Revenue: Revenue increased by $224,008 to $274,722 for the three months ended March 31, 2015, as compared to $50,714 for the three months ended March 31, 2014. This increase in revenue is primarily attributable to the Company’s collaboration agreement with Merck.
I am a long frustrated holder of TINY. Will its Net Asset Value see any joy from this public offering? Does anyone have insights about the newly listed company? Is $16M sufficient for execution of their plans?